Physician profile
Ronald Harrison
NPI 1073049813
$8,934.49
in general payments reported to CMS, 2019-2025
35 companies · $1,824 in 2025
The $1,824 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $310 · 2022: $2,056 · 2023: $2,549 · 2024: $2,195 · 2025: $1,824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,568.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,406.08 | 2022-2025 | |
| Pfizer INC. | $1,086.44 | 2022-2025 | |
| Glaxosmithkline, LLC. | $1,038.08 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $978.45 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $880.43 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $478.02 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $349.07 | 2021-2025 | Otezla, Repatha, Repatha |
| Corium, LLC | $343.64 | 2023-2025 | Azstarys |
| Bayer Healthcare Pharmaceuticals INC. | $293.47 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.34 | 2022-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $233.24 | 2021-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $216.36 | 2021-2023 | Trintellix |
| Exact Sciences Corporation | $190.56 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $178.85 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $134.12 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $129.12 | 2021-2025 | Gardasil 9, Capvaxive, Gardasil |
| Daiichi Sankyo INC. | $109.04 | 2022-2023 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.09 | 2022-2024 | Xifaxan |
| Abbott Laboratories | $87.78 | 2024 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $70.66 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $50.19 | 2024-2025 | Voquezna |
| Supernus Pharmaceuticals, INC. | $45.58 | 2022-2023 | Qelbree |
| Sanofi-Aventis U.S. LLC | $37.50 | 2021-2023 | |
| Atland Pharmaceuticals, LLC | $36.13 | 2025 | Orphenadrine Citrate, Aspirin and Caffeine, Tolmetin Sodium |
| Corcept Therapeutics | $24.62 | 2025 | Korlym |
| Almatica Pharma LLC | $22.86 | 2025 | Loreev Xr, Teriparatide |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.43 | 2025 | Caplyta |
| Dexcom, INC. | $18.27 | 2024 | Dexcom G6 Transmitter |
| Acadia Pharmaceuticals INC | $17.88 | 2021 | |
| Astellas Pharma US INC | $15.67 | 2023 | Myrbetriq |
| Genentech USA, INC. | $15.13 | 2023 | Xofluza |
| Biohaven Pharmaceuticals, INC. | $14.13 | 2021 | |
| Sumitomo Pharma America, INC. | $13.94 | 2025 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $13.48 | 2025 | Camzyos |
| Teva Pharmaceuticals USA, INC. | $12.84 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.